Fast_Eddie_Felson Posted - 6 minutes from now

$ZYME starting to look like junk again. The news literally had 0 impact. Now silence for awhile…the run up was to 17 and thats it.

lucabrix Posted - 1 day ago

$ZYME

topstockalerts Posted - 11/29/24

Top Gainers PT2 $EEFT $ZYME $SNSE $AIFU $SSP Details: https://topstockalerts.com/market-gainers-and-losers/

lucabrix Posted - 11/27/24

$ZYME Reply

Ballz_Deep_In_Gains Posted - 11/27/24

$COLL $EOLS $ZYME The only one with FOMO is you regarding MYNutZ.

lucabrix Posted - 11/26/24

$ZYME 50MA seems a strong support

Rajeshbuffet Posted - 11/26/24

$CKPT $DCTH $JAZZ $XBI $ZYME

Night_Owl_Biotech Posted - 11/24/24

Attached is a list of all 25 new commercial-stage oncology focused bios since 1/1/2019 with a market cap of less than $7.5B noting valuation, FY27 consensus & resulting FY27 multiple. The 10 new to FY2024 are highlighted including $ZYME from last week. $CKPT is nearing. Some believe oncology focused bios with this profile (less than $7.5B market cap) are more likely to be acquired now that the uncertainty from the election has passed. Our educated guesses for near-term M&A in this peer group. 1. SWTX 2. IOVA 3. ZYME (via $JAZZ) 4. DAWN 5. $DCTH Since they are educated guesses we will probably be proven wrong. This is not investment advice. $XBI

Article_AI Posted - 11/24/24

$ZYME Zymeworks Gains Buy Rating Amid FDA Approval and Market Expansion Potential for Zanidatamab In a report released on November 21, David Martin PhD from Bloom Burton maintained a Buy rating on Zymeworks (ZYME – Research Report), with a price... https://www.stck.pro/news/ZYME/94097340/

FactsPlease99 Posted - 11/24/24

$ZYME keep in mind its a very small market means limited growth for now. I don’t see much movement on this one until other indications. IMO

NyseDayTrader Posted - 11/22/24

$ZYME I flattened out on this miniscule bounce today. Its bye for now but not forever ZYME ;)

maplelakeduckslayer Posted - 11/22/24

$ZYME HC Wainwright posts it's "analysis" 5 times since Sept 18...pretty normal 🤣

lucabrix Posted - 11/22/24

$ZYME 50MA seems to be a good support. This price is really irrealistic, way to run up!!

NorthShoreTrader2021 Posted - 11/21/24

$ZYME I will consider buying if the price bound off the 200 MA around $11. short term bearish-long term bullish.

lucabrix Posted - 11/21/24

$ZYME "Zymeworks has earned a milestone payment of $25M based on the FDA approval in BTC. Zymeworks is also eligible to receive up to a further $500M in regulatory milestone payments and $862.5M in commercial milestone payments, as well as tiered royalties of 10% to 20% of net sales by Jazz." ZYME down 6% with Market Cap of 950M??? INSANE!!!!

buylowandwait Posted - 11/21/24

$ZYME Today’s move is not a representation of the direction this little gem is going. 1) big milestone and fat Royalty for a blockbuster drug ! 2) deep pipeline and asset 3) tons of cash with no dilution risk 4) Jazz would buyout this for its own benefit. Look at historical price, you’ll know the direction …

Scientwist Posted - 11/21/24

$ZYME With FDA approval for Ziihera® and a strong pipeline, Zymeworks is poised for significant growth. Limited competition and upcoming revenue streams make this a solid long-term hold. Recent dip is a buying opportunity! This is one of my favorites and i am happy for their success. As soon as these short term traders and short selling mfkers are gone this will skyrocket! 🚀📈 #Bullish #LongTermHold

jimmythetulip Posted - 11/21/24

$ZYME this is incredibly disappointing

maplelakeduckslayer Posted - 11/21/24

$ZYME unexpected disappointing move but we've seen a lot of these drops lately followed by full recovery and going higher in following days in bio. Well see. It seems like a shake to cover shares now that this is derisked post approval. But...obviously the instant gratification of a gap up would have been nicer Jazz has conference call on approval Dec 11 where I'm sure they'll discuss some strategy/sales expectations etc followed by ZYME r and d day Dec 12. These events should give some more insight on direction

zztopps Posted - 11/21/24

$ZYME Shorts determined not to go quietly. Payback will be glorious.

NyseDayTrader Posted - 11/21/24

$ZYME what are we missing here? bought more @ $14

OpenOutcrier Posted - 11/21/24

$ZYME (+10.0% pre) $JAZZ Jazz stock Zymeworks stock gain on FDA nod - SA https://ooc.bz/l/48936

briefingcom Posted - 11/21/24

Gapping up: $SMLR +24% $MSTR +13.3% $MARA +11.1% $ZYME +9.6% $VEEA +8.2%

Mikelonggggggggg Posted - 11/21/24

$ZYME SHORTS!

maplelakeduckslayer Posted - 11/21/24

$ZYME lot of shorts trapped on this one...tutes hold 93% of the 70 mil outstanding with 4.7 mil shares short....the entire free float is short on this🤣

NyseDayTrader Posted - 11/21/24

$ZYME This can be an interesting move with the float being tightly held and 7% short.

Chetlay Posted - 11/21/24

$ZYME Great day for those stuck with this one! Congrats to longs!

turk123 Posted - 11/21/24

$ZYME game changer for this stock!!!

turk123 Posted - 11/21/24

$ZYME $25 soon!!!!!!fda approval

DonCorleone77 Posted - 11/21/24

$JAZZ $ZYME Zymeworks, Jazz Pharmaceuticals announce FDA approval of Ziihera Zymeworks (ZYME) announced, with Jazz Pharmaceuticals (JAZZ), that the U.S. FDA has granted accelerated approval of Ziihera 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer, as detected by an FDA-approved test. Ziihera was approved under accelerated approval based on a 52% objective response rate and a median duration of response of 14.9 months as determined by independent central review. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. The approval of Ziihera, which previously received Breakthrough Therapy Designation from the FDA for this indication, is an important advance and offers the first and only dual HER2-targeted bispecific antibody and chemotherapy-free treatment for patients living with BTC. In late 2022, Zymeworks entered into a license and collaboration agreement with Jazz Pharmaceuticals Ireland Limited, for the exclusive development and commercialization rights to zanidatamab across all indications in the United States, Europe, Japan and all other territories except for those Asia Pacific territories previously licensed by Zymeworks. This collaboration allowed the company to leverage Jazz's global commercial infrastructure, together with BeiGene's complementary strengths in certain Asia Pacific countries, to enable the global, rapid advancement of zanidatamab in multiple tumor types with the potential to provide a foundational HER2-targeted therapy for patients with difficult-to-treat cancers and limited treatment options. Under the terms of the Jazz license and collaboration agreement, Zymeworks has earned a milestone payment of $25M based on the FDA approval in BTC. Zymeworks is also eligible to receive up to a further $500M in regulatory milestone payments and $862.5M in commercial milestone payments, as well as tiered royalties of 10% to 20% of net sales by Jazz.